ストックスクリーナーアプリを入手
12.24
4.23%
-0.54
Neuropace Inc (NPCE) 最新ニュース
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
After shares were withheld for taxes, NeuroPace (NPCE) medical chief Martha Morrell held 51,357 shares. - Stock Titan
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Form 4 Neuropace Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Neuropace Inc For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Neuropace Inc For: 22 September - Investing.com India
NeuroPace CFO Patrick Williams Discloses Tax-Related Share Withholding on RSU Vesting - kalkinemedia.com
NeuroPace (NPCE) CFO has 1,162 shares withheld for taxes - Stock Titan
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE - MarketBeat
First Light Asset Management, LLC Adds 1.34 Million NeuroPace In - GuruFocus
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? - Yahoo Finance
First Light Asset Management LLC Boosts Stake in NeuroPace, Inc. $NPCE - MarketBeat
NeuroPace Inc. (NPCE) Eases 1.76% to $14.50 as Shares Sit Mid-Range Between Support and ResistanceVolume Gap - siam.in
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com India
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com Canada
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com UK
NeuroPace at Wells Fargo conference: IGE push faces FDA test By Investing.com - Investing.com Canada
NeuroPace at Wells Fargo conference: IGE push faces FDA test By Investing.com - Investing.com India
NPCE: Strong clinical data and regulatory progress position the RNS system for significant growth in epilepsy care - tradingview.com
NeuroPace at Wells Fargo conference: IGE push faces FDA test - Investing.com
NeuroPace (NPCE) CEO uses 1,310 shares to cover taxes - Stock Titan
Over 12% of NeuroPace (NPCE) may be owned by one investor - Stock Titan
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now - Yahoo Finance
Man Group plc Makes New $1.34 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc. - MarketBeat
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - marketscreener.com
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - Business Wire
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference - Business Wire
Wells Fargo conference to feature NeuroPace fireside chat Sept. 8 - Stock Titan
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) CEO settles RSU tax bill with 1,126 shares - Stock Titan
NeuroPace (NASDAQ: NPCE) CMO has 358 shares withheld for taxes - Stock Titan
NeuroPace Inc (NPCE) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Neuropace (NPCE) Results Check: EPS Lands Above Forecast; Share Move: Shares Finish 1.22% Up on the DayGeographic Revenue Trends - dars.gov.et
Deutsche Bank AG Acquires Shares of 938,919 NeuroPace, Inc. $NPCE - MarketBeat
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseMFI Oversold - vinanet.vn
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseNHNL Ratio - dars.gov.et
Neuropace (NPCE) Market: Posts a 0.07% Gain to $14.03 in the Current Update; Technical View: the $13.33 to $14.73 Range Remains in Focus in Latest TradingPassive Flow - vinanet.vn
HC Wainwright Has Positive Outlook of NeuroPace Q3 Earnings - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for NeuroPace - MarketBeat
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayTrend Following Picks - vinanet.vn
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayWave Equality - dars.gov.et
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayQuality ETF - dars.gov.et
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Yahoo Finance
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? - Yahoo Finance
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - Yahoo Finance
5.59%
大文字化:
|
ボリューム (24 時間):